A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy

V. A. Ferro, J. H. Morris, W H Stimson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.

Original languageEnglish
Pages (from-to)13-25
Number of pages13
JournalDrug Design and Discovery
Volume13
Issue number1
Publication statusPublished - Aug 1995

Keywords

  • antibodies
  • antibody specificity
  • bacterial proteins
  • boron compounds
  • boron neutron capture therapy
  • small cell carcinoma
  • cell death
  • tumor cells
  • lung neoplasms
  • polyglutamic acid
  • polylysine
  • streptavidin

Cite this